Since the beginning of 2026, shares of CRISPR Therapeutics (CRSP) are down by about 11%. While that’s not a great start to ...

One stock that's been on my watch list for a while is CRISPR Therapeutics (NASDAQ: CRSP). The company has an intriguing business, as not only could it generate a lot of revenue in the future, but it ...

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months.

ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.

CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately. Shares have dropped 5% over the past week and are down 8% year-to-date, trading around $49.37 as of Tuesday morning. Piper Sandler, ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value of over $551 million as of Q4 2025. The gene-editing company remains on ...

CRISPR Therapeutics CRSP is expected to report third-quarter 2025 earnings later this week. The Zacks Consensus Estimate for quarterly sales is pegged at $6.71 million, while that for earnings is ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, analyst Mitchell Kapoor from H.C. Wainwright reiterated a “Buy” rating on ...

Multiple analysts have issued price targets for $CRSP recently. We have seen 15 analysts offer price targets for $CRSP in the last 6 months, with a median target of ...